CDP-choline, also called citicoline, is a naturally occurring intermediate in the pathway that builds the membrane phospholipid phosphatidylcholine. It provides components relevant to choline signaling and membrane metabolism. The page reviews research on cognitive function, cerebrovascular conditions and neurological processes, while noting mixed clinical findings.
For broader research context on nootropic compounds, including comparative stacks, cycling considerations, and interaction notes, see the Complete Nootropic Cheat Sheet.
What Is CDP-Choline (Citicoline)?
CDP-choline, or cytidine diphosphocholine, is a water-soluble nucleotide derivative composed of cytidine, diphosphate, and choline. It is also known as citicoline and is an endogenous intermediate in the Kennedy pathway, the principal biochemical route for synthesizing phosphatidylcholine. Phosphatidylcholine is a major structural phospholipid in neuronal and other cellular membranes, and it contributes to membrane integrity, vesicle formation, myelin maintenance, and lipoprotein metabolism. Citicoline is available as an oral supplement and, in some countries, as a pharmaceutical product administered orally, intravenously, or intramuscularly.
After oral administration, citicoline is extensively hydrolyzed during absorption into choline and cytidine-related compounds, including uridine in some tissues, and these components are subsequently taken up and recombined in cells. This dual-substrate profile distinguishes citicoline from choline salts and from isolated cytidine or uridine supplements. Research has examined citicoline as a potential support for cholinergic neurotransmission, phospholipid synthesis, mitochondrial and membrane function, dopamine signaling, and recovery from neural injury. It is not an established treatment for dementia, stroke, glaucoma, attention disorders, or any other disease, and clinical results have been mixed, particularly in acute stroke trials.
Quick Reference
Member reference tables summarize the compound's research parameters.
Clinical studies have examined prolonged oral citicoline administration for cognitive impairment following cerebrovascular events, with some trials reporting improvements on cognitive measures.
Memory and attention
Human research in older adults and individuals with memory complaints has investigated citicoline for attention, memory performance, and processing speed; results vary by population and study design.
Cerebrovascular Research
Supported Research
Acute ischemic stroke
Citicoline has been evaluated as an adjunct in acute ischemic stroke trials. Large studies have produced mixed findings and it is not a replacement for time-sensitive emergency stroke care.
Neuronal membrane metabolism
As a precursor to phosphatidylcholine, citicoline is studied for effects on phospholipid synthesis, membrane repair pathways, and choline availability.
Mood and Motivation
Preliminary Data
Mental energy and motivation
Anecdotal use and limited exploratory research describe possible effects on mental energy and motivation, but robust controlled evidence for mood outcomes remains limited.
Dopaminergic signaling
Preclinical work suggests citicoline may influence dopamine-related pathways. The clinical significance of these findings in healthy adults is uncertain.
Visual and Neurological Function
Emerging Evidence
Glaucoma and optic nerve research
Small studies have explored citicoline as an adjunct in glaucoma and optic nerve conditions, often using non-oral formulations. Evidence is insufficient for self-treatment.
Traumatic brain injury
Citicoline has been investigated in neurological injury contexts, but its role in traumatic brain injury recovery remains unsettled and requires clinician-directed care.
Research Protocols
As reported in cited literature and research-community logs (see Research Citations below), not a personal dosing recommendation.
This member section describes parameters reported in the research literature.
Included for harm-reduction awareness only, in the event this compound is encountered outside its labeled research use. Inclusion here does not imply RUO Codes endorses, recommends, or instructs human use.
This member section discusses research safety considerations and uncertainties.
The described verification process includes looking for CDP-choline or citicoline clearly identified on the label, with the amount specified per capsule or serving.
Verified Marker
Recent batch-specific COA
A certificate of analysis should identify the lot number and report identity and assay testing for the finished ingredient or batch.
Verified Marker
Independent contaminant testing
Prefer products with third-party testing for heavy metals and microbiological contaminants, particularly for frequent long-term oral use.
Acceptable Range
Capsule and dose transparency
Capsules or tablets should state the exact milligrams of citicoline per unit and list all excipients; the listed text specifies avoiding relying on proprietary blends.
Quality Concern
No accessible purity documentation
The listed research text specifies avoiding products that do not provide lot traceability, HPLC or equivalent purity information, or credible testing documentation when requested.
Research Citations
Citicoline: pharmacological and clinical review, 2016 update Secades, J. J., 2016, CNS Drugs